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INTRODUCTION 
Post-transplant lymphoproliferative disorder (PTLD) is a well 
recognized complication after transplantation, and has been 
reported to occur in approximately 2% of organ transplant 
recipients both with Cyclosporine and FK506 immunosuppression 
(1-6). The use of FK506 in clinical small bowel transplantation 
has resulted in improved patient and graft survival (7). This 
report describes the clinical and pathologic features of (PTLD) 
arising in intestinal transplant recipients treated primarily with 
FK506. This complication has been known to be a special risk of 
intestinal transplantation since the first reports of long survival 
of multivisceral recipients who were treated with cyclosporine 
(8,9) . 
MATERIAL AND METHODS 
Case Material: Between May 2, 1990 and August 7, 1993 a total 
of 54 patients received intestinal transplants with or without 
other abdominal organs using FK506 as their primary 
immunosuppressive therapy. This group comprised 18 isolated 
intestine recipients (I), 26 liver/intestine recipients (L/I) , and 
10 multivisceral recipients (MV) (1 MV without the liver or 
modified multivisceral). Within this population 29 pediatric 
patients were transplanted, including 5 I, 20 L/I, and 4 MV 
recipients. 
Immunosuppressive therapy (induction, and treatment of 
rej ection) was as previously described and based on FK506 as 
primary drug (7). 
Pathologic Studies: All available surgical and autopsy 
specimens as well as EBV serologic data were reviewed. The 
evaluation of PTLD lesions included histopathology, analysis of 
clonal status, and demonstration of EBV (by in-situ hybridization 
for EBER). 
RESULTS 
Patient population and Tumor Incidence: A total of 8 cases of 
PTLD were identified. Four occurred in males and 4 occurred in 
females (M:F ratio, 1/1). The age of these recipients at the time 
of transplantation ranged from 1.7 to 44 years. six patients were 
children, with a mean age of 4.1 years. The time between the date 
of organ transplant and the date of disease presentation ranged 
between 24 days and 2.3 years, however, 6 patients presented after 
10 months post-transplant (mean of 1.2 years). These 8 cases 
represent 14.8% of the total study population. The overall 
incidence in adult recipients was 8%, and the overall incidence in 
pediatric recipients was 20.6%. The distribution of cases relative 
to the graft type revealed 5 cases in L/I grafts, and 3 cases in MV 
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grafts. Interestingly, the 2 adult patients were recipients of MV 
grafts. 
Clinical Presentation and Location of PTLD: Symptoms of 
fever, weight loss and malaise were common (4 patients), however, 
nonspecific, initiating a work-up and a search for infection and/or 
rejection. One patient presented with hemolysis and diarrhea. A 
lymphadenopathic presentation was noted in 2 patients (22%) and 
localized to the head and neck region in one patient and 
generalized in the other. six patients (66.6%) had involvement of 
the gastrointestinal tract presenting as nodular ulcerated tumors. 
The intestinal graft was involved with disease in 5 patients 
(55.5%) and generally presented with vomiting, diarrhea and 
gastrointestinal bleeding. Of these, 2 patients developed 
complications related to their graft which included bleeding and 
intestinal perforation. One patient presented isolated right lung 
involvement. After resolution of this tumor she later presented 
spindle cell tumors in the native colon which was positive for EBV 
at in-situ hybridization studies. One patient presented fulminant 
disseminated disease, a recipient of an MV graft who received 
intensive therapy for early exfoliative type rejection of the 
intestine. He developed early onset disease ( involving all 
thoracic and abdominal organs) and died of fulminant PTLD and 
mUltisystem organ failure at 2 months post-transplant. Of note, 
PTLD was identified on routine endoscopy without associated 
symptoms in 2 patients. 
Pathologic Features of PTLD: The evaluation of PTLD in this 
3 
series was hindered by sample size and necrosis (when ulcers were 
present). The range of histology was that of activated lymphocytes 
with a polymorphic appearance, which was seen in all patients. 
Clonal analysis was feasible in only 4 cases; the lesions were 
monoclonal in all cases studied. Evidence of EBV DNA was found in 
all specimens. 
Serologic evidence of EBV infection was found in all patients, 
7 were non primary infections, and 1 was primary. 
Treatment: Treatment consisted of reduction in 
immunosuppression 
gancyclovir for 
combined with intravenous acyclovir or 
as long as there were lesions present. 
Alpha-interferon and/or Foscarnet were used in selected cases where 
there seemed to be rapid progression of disease, extensive disease, 
recurrent disease, or there had been a history of severe rejection 
and immunosuppression could not be reduced. In 2 cases the 
immunosuppression being utilized was stopped entirely while there 
was evidence of clinical disease. In 1 patient immunosuppression 
was not reduced because of previous repetitive rejections. This 
patient had resolution of lesions on gancyclovir and alpha-
interferon. Lesions were followed by a combination of endoscopy, 
and radiologic studies (CT scans, plain and contrast films, etc.). 
outcome: Five of the 8 patients diagnosed with PTLD have 
survived (mortality of 37.5%) with a mean follow-up of 20 months. 
Four of these surviving patients have had complete remission of 
their disease, whereas 1 patient continues to have lesions and is 
under therapy. Four surviving patients have retained their grafts. 
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All of these patients are presently on maintenance 
immunosuppression using FK506. Four patients developed rejection 
after resolution of there PTLD and required aggressive therapy. 
Three patients were treated successfully with resumption of 
maintenance FK506 therapy and steroids; 1 patient was 
retransplanted. 
The deaths in this series of PTLD occurred in recipients of 
L/I (n=2) and MV (n=l) grafts. The median time from transplant to 
death as a result of PTLD was 15 months. Of these 3 patients who 
died all were identified as having residual PTLD at autopsy. Both 
fatalities (66%) presented severe bacterial and fungal infection as 
well as multi system organ failure. One of these patients 
presented perforation and bleeding of the PTLD lesions. Two of 
these patients who died had received OKT3 sometime during there 
course. One patient died of iatrogenic administration of an 
excessive amount of enteral sodium after successful treatment of 
PTLD. He was found to have recurrent PTLD at autopsy. 
DISCUSSION 
Three identifiable factors could contribute to the higher 
incidence of PTLD (14.8%) in these intestinal transplant 
recipients: the lymphoid content of the graft, the aggressive 
immunotherapy required in these cases, and earlier diagnosis in 2 
patients in whom the EBV was identified by in-situ hybridization. 
One patient who was at the lower end of the EBV infection spectrum 
before clonal expansion and tumor development was diagnosed after 
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presentation with minimal enlargement of cervical lymph node and 
Flu-like symptoms. Hopefully, early diagnosis will improve 
treatment response. 
The time of PTLD onset in these intestinal recipients was 
later (>10 months) 
transplants (1,5). 
aggressive disease, 
than in recipients of other kinds of organ 
However, there were 3 examples of early 
from which 2 patients died. The spectrum of 
lesions was peculiar in that histologically the PTLD's were all 
within the range of a polymorphic pattern. Also, monoclonality was 
found in the 4 patients studied, 2 patients with severe disease and 
2 patients with a mononucleosis like picture. The occurrence of 
spindle cell lesions in 2 patients reflects a significant, as of 
yet unexplained, deviation from the expected pattern. 
Complications of PTLD (infections, bleeding, perforation) and late 
diagnosis have been responsible for death in 2 patients. 
Gastrointestinal involvement, of both native and transplanted 
gut, was the most common site of presentation. A lymphodenopathic 
presentation is amenable to a rapid and complete remission of their 
disease, with preservation of graft function. 
The mainstay of therapy is above all reduction of 
immunosuppression to which intravenous acyclovir or gancyclovir is 
an adjuvant measure. The risk of complete discontinuation of 
treatment is rejection which led to retransplantation in 1 patient 
and left another child with a marginal graft. PTLD was treated 
successfully in 1 child while maintaining base line 
immunosuppression. 
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The role of alpha-interferon and Foscarnet for the treatment 
of any PTLD in organ transplant recipients remains to be 
determined. These agents may be regarded as adjuvant to reduction 
of immunosuppression in patients with severe disease, or as primary 
treatment in selected patients for whom reduction of 
immunosuppression would carry a high risk of rejection. 
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